Consensus Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			After market 06:10:42 pm
16.64 ^USD	+8.19%		16.84	+1.17%

Apr. 23	Day One Biopharmaceuticals Shares Rise; FDA Issues Accelerated Approval for Pediatric Low-Grade Glioma Treatment	MT
Apr. 23	Day One Biopharmaceuticals Drug Tovorafenib Gets FDA Accelerated Approval	DJ

Evolution of the average Target Price on Day One Biopharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

33301576.ZxkIvX7BE1BpbjqxL952VFHYlrcbUKbDeDLkDKHvH0M.I1xc8wuqQTEqPm7HbJxFFRaaotJDE833MVqIQNCcVC0oTm2MHataZg4cdw~462e4a1834e07a44802f205351a6cade

Analyst Recommendations on Day One Biopharmaceuticals, Inc.

JPMorgan Raises Price Target on Day One Biopharmaceuticals to $36 From $32, Maintains Overweight Rating	Apr. 22	MT
Piper Sandler Cuts Price Target on Day One Biopharmaceuticals to $40 From $45, Maintains Overweight Rating	Feb. 28	MT
Wedbush Adjusts Day One Biopharmaceuticals' Price Target to $33 From $35, Keeps Outperform Rating	Feb. 27	MT
Goldman Sachs Cuts Price Target on Day One Biopharmaceuticals to $44 From $50, Maintains Buy Rating	Feb. 27	MT
Wedbush Lowers Day One Biopharmaceuticals' Price Target to $35 From $39, Keeps Outperform Rating	Nov. 07	MT
Wedbush Lifts Day One Biopharmaceuticals' PT to $39 From $38 After Tovorafenib Receives Priority Review, Maintains Outperform Rating	23-10-31	MT
Goldman Sachs Lowers Price Target on Day One Biopharmaceuticals to $54 From $63, Maintains Buy Rating	23-08-08	MT
HC Wainwright Raises Price Target on Day One Biopharmaceuticals to $50 From $45, Keeps Buy Rating	23-06-05	MT
Needham Cuts Price Target on Day One Biopharmaceuticals to $40 From $44, Maintains Buy Rating	23-05-08	MT
BofA Securities Downgrades Day One Biopharmaceuticals to Underperform From Buy, Adjusts Price Target to $9 From $34	23-04-25	MT
Needham Adjusts Price Target on Day One Biopharmaceuticals to $44 From $48, Keeps Buy Rating	23-04-05	MT
Capital One Starts Day One Biopharmaceuticals at Overweight With $40 Price Target	23-02-08	MT
Oppenheimer Initiates Coverage on Day One Biopharmaceuticals With Perform Rating	23-02-03	MT
Piper Sandler Adjusts Day One Biopharmaceuticals' Price Target to $45 From $40, Keeps Overweight Rating	23-01-09	MT
HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $45 From $35, Maintains Buy Rating	23-01-09	MT
Goldman Sachs Adjusts Price Target on Day One Biopharmaceuticals to $62 From $45, Maintains Buy Rating	23-01-09	MT
Wedbush Raises Day One Biopharmaceuticals' PT to $38 From $35 After Positive Topline Results From FIREFLY-1 Study, Keeps Outperform Rating	23-01-09	MT
HC Wainwright Initiates Coverage on Day One Biopharmaceuticals With Buy Rating, $35 Price Target	22-12-15	MT
Needham Initiates Coverage on Day One Biopharmaceuticals With Buy Rating, $40 Price Target	22-12-14	MT
Goldman Sachs Initiates Day One Biopharmaceuticals With Buy Rating, Sets Price at $45	22-12-05	MT
BofA Securities Starts Day One Biopharmaceuticals at Buy With $34 Price Target	22-12-01	MT
Piper Sandler Adjusts Price Target on Day One Biopharmaceuticals to $40 From $35, Reiterates Overweight Rating	22-06-21	MT
Wedbush Lifts Price Target on Day One Biopharmaceuticals to $35 From $32, Citing Tovorafenib Data; Outperform Rating Kept	22-06-13	MT
Wedbush Removes Outperform-Rated Day One Biopharmaceuticals From Best Ideas List; Price Target is $32	22-05-13	MT
Wedbush Adds Outperform-Rated Day One Biopharmaceuticals to Best Ideas List; Price Target is $32	22-03-11	MT